Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trial

Autor: Wolfgang Nachbauer, Ilaria Giordano, Ingrid Berger, Jens Claassen, Christine Adrion, Ivonne Naumann, Otmar Bayer, Thomas Klopstock, Ulrich Mansmann, Bart P.C. van de Warrenburg, Thomas Klockgether, Claudia Stendel, Katharina Feil, Heike Jacobi, Julian Teufel, Michael Strupp, Sylvia Bösch, Hans-Helge Müller, Ludger Schöls, Holger Hengel, Ellen Uslar

Publikováno v: BMC Neurology
BMC Neurology, 17, 7
BMC neurology 17(1), 7 (2017). doi:10.1186/s12883-016-0786-x
BMC Neurology, 17, 1, pp. 7

Cerebellar ataxia (CA) is a frequent and often disabling condition that impairs motor functioning and impacts on quality of life (QoL). No medication has yet been proven effective for the symptomatic or even causative treatment of hereditary or non-h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::353436a27b7732aec3d7b06a70edd90b
https://pubmed.ncbi.nlm.nih.gov/28068987